1. Scrip
  2. >>Therapy Areas

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

 
• By Jessica Merrill

Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.

women's handshake
Organon partnered with ObsEva in women's health • Source: Alamy

Organon is making good on its promise to investors that it will build out its women's health portfolio. The company announced its first licensing deal on 27 July, in its second month after spinning out from Merck & Co. Organon bought worldwide licensing rights to ebopiprant for acute preterm labor in a deal with Swiss women's health specialist ObsEva SA.

Ebopiprant is a potential first-in-class selective prostaglandin F2α (PGF2α) receptor antagonist that could treat preterm labor by reducing inflammation and uterine contractions. There are currently no approved therapies for acute...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.